It has now been nearly two months since BELLUS Health announced that its lead candidate KIACTA™ had not met its primary endpoint in the Phase 3 study completed earlier this year. The shares are 89% down since the news. The company’s recent Q3 release however tells us Shigamab™, a wholly owned programme, has shown further very strong pre-clinical data for sHUS this time in a primate model, and reminds us that BELLUS Health holds interests in a number of third party programmes
15 Aug 2016
BELLUS Health – Taking Stock
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BELLUS Health – Taking Stock
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.66m
- Published:
15 Aug 2016 -
Author:
Derren Nathan -
Pages:
6
It has now been nearly two months since BELLUS Health announced that its lead candidate KIACTA™ had not met its primary endpoint in the Phase 3 study completed earlier this year. The shares are 89% down since the news. The company’s recent Q3 release however tells us Shigamab™, a wholly owned programme, has shown further very strong pre-clinical data for sHUS this time in a primate model, and reminds us that BELLUS Health holds interests in a number of third party programmes